BLA 021106 · Pharmacia
Somavert
Pegvisomant · Subcutaneous
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 27, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Mar 25, 2003
Approved uses
3
Original approval plus efficacy supplements
Registered trials
31
5 Phase 3, 1 recruiting
FAERS reports
4,106
2,291 serious, 320 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 18, 2025.
SOMAVERT is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels. SOMAVERT is a growth hormone receptor antagonist indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels. ( 1 )
Mechanism: Pegvisomant selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of IGF-1, as well as other GH-responsive serum proteins such as free IGF-1, the acid-labile subunit of IGF-1 (ALS), and insulin-like growth factor binding protein-3 (IGFBP-3).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 27, 2023 Supplement 74 · Efficacy OrphanLetterLabel
- Dec 10, 2013 Supplement 36 · Efficacy LetterLabel
- Mar 25, 2003 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
5 products under this application
- SOMAVERT · PEGVISOMANT 30MG/VIAL · INJECTABLE, SUBCUTANEOUS · Prescription
- SOMAVERT · PEGVISOMANT 20MG/VIAL · INJECTABLE, SUBCUTANEOUS · Prescription
- SOMAVERT · PEGVISOMANT 10MG/VIAL · INJECTABLE, SUBCUTANEOUS · Prescription
- SOMAVERT · PEGVISOMANT 25MG/VIAL · INJECTABLE, SUBCUTANEOUS · Prescription
- SOMAVERT · PEGVISOMANT 15MG/VIAL · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pegvisomant" as an intervention, any sponsor and status, largest first.
- Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsPivotal-lookingCompleted
IpsenIndustry
NCT00383708 · 125 participants · Start Oct 2006 · Primary completion Oct 2008
Drug: lanreotide (Autogel formulation); Pegvisomant · For: Acromegaly
Sites: Hradec Králové, Czechia; Prague, Czechia; Aarhus, Denmark · 24 sites in all
- A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With AcromegalyPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00068042 · 100 participants · Start Apr 2003
Drug: Pegvisomant; Sandostatin LAR · For: Acromegaly
Sites: Los Angeles, California; Chicago, Illinois; Boston, Massachusetts · 55 sites in all
- Acromegaly Combination Treatment StudyTerminated
Cedars-Sinai Medical CenterAcademic, hospital or other
NCT01538966 · 76 participants · Start Mar 29, 2012 · Primary completion May 20, 2022
Drug: Pegvisomant; Octreotide LAR and 1 more · For: Acromegaly
Sites: Los Angeles, California
PfizerPfizer (PFE)
NCT00068029 · 75 participants · Start Oct 2003
Drug: Pegvisomant/ Sandostatin LAR; Sandostatin LAR and 1 more · For: Acromegaly
Sites: Los Angeles, California; Boston, Massachusetts; Chapel Hill, North Carolina · 33 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT01278342 · 70 participants · Start Sep 2006 · Primary completion Nov 2009
Drug: Sandostatin LAR; pegvisomant and 1 more · For: Acromegaly
Sites: Brest, France; Bron, France; Le Kremlin-Bicêtre, France · 20 sites in all
- Pasireotide LAR and Pegvisomant Study in AcromegalyStatus unknown
Erasmus Medical CenterAcademic, hospital or other
NCT02668172 · 60 participants · Start Aug 2015 · Primary completion Mar 2017
Drug: Pasireotide LAR 60 mg; Pegvisomant · For: Acromegaly
Sites: Rotterdam, Netherlands
Vanderbilt UniversityAcademic, hospital or other
NCT01701973 · 44 participants · Start Jan 2013 · Primary completion May 2017
Drug: Sitagliptin; Pegvisomant and 3 more · For: Obesity
Sites: Nashville, Tennessee
PfizerPfizer (PFE)
NCT00151437 · 30 participants · Start Nov 2004
Drug: Pegvisomant treatment · For: Acromegaly
Sites: Edmonton, Canada; Halifax, Canada; Toronto, Canada · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use491
- drug ineffective438
- headache404
- fatigue387
- insulin-like growth factor increased380
- arthralgia300
- product dose omission issue268
- injection site pain261
- diarrhoea256
- nausea231
- pain213
- blood pressure increased206
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 23 |
| 2005 | 35 |
| 2006 | 39 |
| 2007 | 22 |
| 2008 | 23 |
| 2009 | 38 |
| 2010 | 88 |
| 2011 | 73 |
| 2012 | 102 |
| 2013 | 156 |
| 2014 | 164 |
| 2015 | 176 |
| 2016 | 181 |
| 2017 | 276 |
| 2018 | 382 |
| 2019 | 402 |
| 2020 | 354 |
| 2021 | 245 |
| 2022 | 350 |
| 2023 | 455 |
| 2024 | 261 |
| 2025 | 196 |
| 2026 | 65 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Somavert (PEGvisomant)
2024 spending
$37.3M
Beneficiaries
257
2,381 claims
Per beneficiary
$145,112
$533.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $36,050,937 |
| 2021 | $33,892,085 |
| 2022 | $35,283,015 |
| 2023 | $37,083,662 |
| 2024 | $37,293,740 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of pharmacologic therapies in acromegaly: a systematic literature review and network meta-analysis.
Salvatori R, Colzani RM, Hummel N, et al. · J Clin Endocrinol Metab 2026 · Systematic Review, Network Meta-Analysis
- Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies.
Leonart LP, Tonin FS, Ferreira VL, et al. · Endocrine 2019 · Meta-Analysis, Systematic Review
- Pegvisomant Improves Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies.
Feola T, Cozzolino A, Simonelli I, et al. · J Clin Endocrinol Metab 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Second line treatment of acromegaly: Pasireotide or Pegvisomant?
Chiloiro S, Bianchi A, Giampietro A, et al. · Best Pract Res Clin Endocrinol Metab 2022 · Meta-Analysis, Review
- Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I, Adnan Z, Gorshtein A, et al. · Endocrine 2018 · Clinical Trial, Phase III, Multicenter Study
- The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.
Franck SE, Broer L, van der Lely AJ, et al. · Neuroendocrinology 2017 · Meta-Analysis, Systematic Review
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.